Compass Pathways has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), tracking the performance of NASDAQ biotechnology/pharmaceutical companies.
Compass Pathways has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), tracking the performance of NASDAQ biotechnology/pharmaceutical companies.
Awakn Life Sciences reports its Q3 for fiscal 2021. Highlights include key IP and clinic acquisitions, and the company's first revenues.
MindMed's Phase IIa clinical trial of LSD for adults ADHD is officially underway, enrolling patients.
MINDCURE moves an important step closer to the full commercial deployment of its iSTRYM digital therapeutics platform, and also makes a key addition to its management team.
HIPAA compliance certification is the next step for the Company in working towards having the iSTRYM technology platform classified a ‘Software as a Medical Device’ by the FDA.
Cybin Inc receives its Notice of Allowance from the USPTO with respect to its patent for CYB004.
MindMed announces that interim CEO Robert Barrow has now been named the permanent CEO, and added as a Director.
atai partner, Recognify Life Sciences, reports positive Phase 2a results in treating Cognitive Impairment Associated with Schizophrenia.
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) announces the appointment of Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”)
The ongoing and worsening mental health crisis in the U.S. military is a national tragedy and a national disgrace. Part I reveals the ugly Big Picture.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now